




<b>Name</b>	Premal Lulla, M.D., M.S.	
<b>Current Position</b>	Associate Professor, Center for Cell and Gene Therapy, Baylor College of Medicine (BCM), Houston	
<b>Country</b>	United States of America	
<b>Major Field</b>	Transplantation and Cellular Therapy	

## Educational Background

1. Medical Education:
  - a. Bachelor of Medicine and Bachelor of Surgery (M.B., B.S., MD equivalent), Maharashtra University of Health Sciences & D.Y. Patil Medical College, Mumbai, India (Rank 3, Distinction Honors) 2002 – 2007
  - b. Pre-graduate Clinical Internship, D.Y. Patil Medical College & Rajawadi Hospital, Mumbai, India 2007 – 2008
2. Postgraduate Training:
  - a. Residency, Internal Medicine. Baylor College of Medicine (BCM), Houston TX 2009 – 2012
  - b. Postdoctoral Clinical Fellowship. Hematology & Oncology BCM, Houston TX 2012 – 2015
  - c. Cellular therapy research Fellow (T32 mentor: Ann Leen PhD, Helen Heslop MD, Malcolm Brenner MD PhD, Margaret Goodell, PhD), Center for Cell and Gene Therapy, BCM, Houston, TX 2014 – 2015
  - d. Chief Fellow, Hematology & Oncology. BCM, Houston TX 2014 – 2015
  - e. Master's in Clinical Investigation, BCM, Houston TX 2020 – 2022

## Professional Experience

- a. Associate Professor, Center for Cell and Gene Therapy, BCM, Houston, TX (Transplantation and Cellular Therapy) 2021 – present
- b. Assistant Professor, Center for Cell and Gene Therapy, BCM, Houston TX 2015 – 2021
- c. Faculty, Translational Biology and Molecular Medicine program (now changed to CTR-CAQ), Graduate School of Biomedical Sciences, BCM, Houston TX 2015 – present
- d. cGMP Medical Director (Cellular Therapy Lab), BCM, Center for Cell and Gene Therapy, Houston TX 2017 – present
- e. Clinical, marrow collections and immune effector cellular therapy inspector, Foundation for the Accreditation for Cellular Therapies (FACT) 2016 – present
- f. Houston Methodist Hospital Apheresis and Cell therapy medical associate 2017 – present
- g. NIH-NCI (National Cancer Institute) Lymphoma SPORE grant clinical PI for project 2 2016 – present
- h. Leukemia Lymphoma Society (LLS) SCOR grant: Immunotherapy of Hematologic malignancies, clinical PI for project 2 2017 – present
- i. Cancer Prevention and Research Institute of Texas (CPRIT) Clinical Investigator Award (ECIA), (CPRIT scholar) 2020 – present

j.	Principal investigator for 9 ongoing sponsored or investigator initiated clinical trials in cellular therapy (see <a href="http://clinicaltrials.gov">clinicaltrials.gov</a> for a current list)	2014 – present
k.	Principal investigator for 4 completed investigator initiated clinical trials in cellular therapy	2014 – 2022
l.	Co-investigator on >20 investigator initiated or sponsored cellular therapy clinical trials	2014 – present
m.	Principal investigator on 4 new investigational new drug submissions to the FDA	2015 – present
n.	Edward P Evans MDS Discovery Research Grant Principal Investigator	2018 – 2021
o.	American Society of Hematology (ASH) junior faculty Scholar	2017 – 2019
p.	American Society of Blood and Marrow Transplantation (ASBMT), New Investigator Award	2016 – 2018
q.	NIH/NCI (National Cancer Institute) SPORE in Lymphoma, Developmental Research Project (DRP)	2017 – 2018
r.	Leukemia Texas Research Grant, Principal investigator	2016 – 2018
s.	Indian council of medical research (ICMR), short-term research studentship, Student principal investigator	2005 – 2006

## Other Experience and Professional Memberships

### National/International Scientific Participation:

1. Journal Editorial Boards:
  - a. Cancer Immunity and Immunotherapy (Frontiers), review editor
  - b. Cytotherapy editorial board
2. Ad hoc journal reviewer:
  - a. Nature Medicine
  - b. Clinical Cancer Research
  - c. Science Translational medicine
  - d. Blood
  - e. Blood Advances
  - f. Journal of Immunotherapy of Cancer
  - g. Biology of Blood and Marrow Transplantation
  - h. Bone Marrow Transplantation
  - i. Molecular Therapy
  - j. Frontiers in Medicine
  - k. Frontiers subsidiaries (Immunology, oncology)
  - l. Therapeutic advances in Hematology
  - m. Therapeutic advances in Medical Oncology
  - n. British Journal of Hematology
3. Review panels:
  - a. California Institute for Regenerative Medicine (CIRM) context expert for GWG study section
  - b. American Society of Hematology Junior Faculty Scholar (Basic Sciences) Study Section
  - c. American Society of Hematology Research training fellow award (RTAF)
  - d. American Society of Hematology abstract reviewer for scientific session in cancer immunotherapy at annual meeting
  - e. Blood Cancer UK Study section, Blood Cancer UK
  - f. Edwards P. Evans Foundation Discovery Research Grant study section
  - g. Bone Marrow Transplant- clinical trials network ancillary review committee for CTN 1901/1902
  - h. LLS Professional Education Symposium reviewer/organizer
  - i. TBMM (graduate student) Research Symposium abstracts
  - j. Society of General Internal Medicine, Abstracts
4. Professional Societies

a. American Association of Cancer Institutes CAR-T steering Committee	2023 – present
b. CIBMTR Cellular Immunotherapy of Cancer Committee	2021 – present
c. CIBMTR Donor Health and Safety Committee	2022 – present
d. Foundation for the Accreditation for Cellular Therapies (FACT) Clinical Outcomes committee member	2021 – present
e. FACT education committee member	2019 – present
f. Inspector, Foundation for the Accreditation for Cellular Therapies (FACT)	2016 – present
g. Member, American Society of Hematology	2015 – present
h. Member, American Society for transplantation and cellular therapy	2015 – present
i. Member, BMT-CTN 1901/02 Protocol Ancillary writing committee	2019 – present
j. Member, American College of Physicians	2009 – 2012
k. Member, Society of General Internal Medicine	2010 – 2012
l. Member, Harris County Medical Society	2011 – 2014

## Main Scientific Publications

1. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill LC, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney C, Vera JF, Leen AM, **Lulla P**. Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL. *Blood*. 2022 Feb 8;blood.2021014648. doi: 10.1182/blood.2021014648. Epub ahead of print. PMID: 35134127.
2. Vasileiou S\*, **Lulla PD\***, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. *J Clin Oncol*. 2021 May 1;39(13):1415-1425. PubMed Central PMCID: PMC8274795. \*denotes equal contribution.
3. **Lulla PD**, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. *Blood*. 2021 May 13;137(19):2585-2597. PubMed Central PMCID: PMC8120140.
4. **Lulla PD**, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. *Sci Transl Med*. 2020 Jul 29;12(554) PubMed PMID: 32727914.
5. Ramos CA, Grover NS, Beaven AW, **Lulla PD**, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. *J Clin Oncol*. 2020 Nov 10;38(32):3794-3804. PubMed Central PMCID: PMC7655020.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/1pS4FEh8ogn5M/bibliography/48521725/public/>